PF-Atlas › Clinical Trials › NCT03911713
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
VX-561 · Phase 2
Registry ID
NCT03911713
Phase
Phase 2
Status
Completed
Drug / intervention
VX-561
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2019-04-17
About this trial
VX-561 is evaluated in NCT03911713, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Vertex Pharmaceuticals Incorporated. Current status: Completed.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT03911713 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.